Clinical Trials Browser

Neoplasm, Residual × Lenalidomide × 90 days × Clear all

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT05690984 2026-03-16

EMAT

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual